In response to: The validity of 18F-GE180 as a TSPO imaging agent

In response to: The validity of ¹⁸F-GE180 as a TSPO imaging agent

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1208-1211. doi: 10.1007/s00259-019-04294-8. Epub 2019 Mar 2.

Nathalie L Albert¹, Marcus Unterrainer², Matthias Brendel², Lena Kaiser², Markus Zweckstetter^{3

4}, Paul Cumming^{5

6}, Peter Bartenstein²

¹ Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. Nathalie.Albert@med.uni-muenchen.de.
² Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
³ Department for NMR-Based Structural Biology, Max Planck Institute for Biophysical Chemistry, Goettingen, Germany.
⁴ German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
⁵ Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland.
⁶ School of Psychology and Counselling and IHBI, Queensland University of Technology, Brisbane, Australia.

No abstract available